CN115427432A - 一种治疗或者预防冠状病毒病突变株的疫苗试剂 - Google Patents

一种治疗或者预防冠状病毒病突变株的疫苗试剂 Download PDF

Info

Publication number
CN115427432A
CN115427432A CN202280003537.6A CN202280003537A CN115427432A CN 115427432 A CN115427432 A CN 115427432A CN 202280003537 A CN202280003537 A CN 202280003537A CN 115427432 A CN115427432 A CN 115427432A
Authority
CN
China
Prior art keywords
amino acid
seq
polypeptide
polynucleotide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280003537.6A
Other languages
English (en)
Inventor
张军
李航文
张育坚
姚卫国
林昂
赵凡凡
马晓颦
黄雷
张静
张玉强
章小铃
沈明云
陈春秀
沈海法
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siwei Shanghai Biotechnology Co ltd
Original Assignee
Siwei Shanghai Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siwei Shanghai Biotechnology Co ltd filed Critical Siwei Shanghai Biotechnology Co ltd
Publication of CN115427432A publication Critical patent/CN115427432A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

涉及生物医药领域，具体涉及预防或治疗冠状病毒感染的疫苗。特别地，提供用于预防或治疗新型冠状病毒感染的多肽、编码其的多核苷酸(特别是mRNA)以及组合物。

Description

PCT国内申请，说明书已公开。

Claims (28)

  1. PCT国内申请，权利要求书已公开。
CN202280003537.6A 2021-02-10 2022-02-10 一种治疗或者预防冠状病毒病突变株的疫苗试剂 Pending CN115427432A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110184684 2021-02-10
CN202110184680 2021-02-10
CN2021101846845 2021-02-10
CN2021101846807 2021-02-10
PCT/CN2022/075895 WO2022171182A1 (zh) 2021-02-10 2022-02-10 一种治疗或者预防冠状病毒病突变株的疫苗试剂

Publications (1)

Publication Number Publication Date
CN115427432A true CN115427432A (zh) 2022-12-02

Family

ID=82837484

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280003537.6A Pending CN115427432A (zh) 2021-02-10 2022-02-10 一种治疗或者预防冠状病毒病突变株的疫苗试剂

Country Status (2)

Country Link
CN (1) CN115427432A (zh)
WO (1) WO2022171182A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117886904A (zh) * 2023-03-31 2024-04-16 上海蓝鹊生物医药有限公司 一种抗新冠病毒的蛋白或mRNA疫苗及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170210698A1 (en) * 2015-09-17 2017-07-27 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
CN111995677A (zh) * 2020-05-15 2020-11-27 潍坊医学院 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用
CN112129871A (zh) * 2020-09-04 2020-12-25 斯微(上海)生物科技有限公司 复合磷脂脂质体中dope和m5两种磷脂含量的检测方法
WO2021019102A2 (en) * 2019-08-01 2021-02-04 Acm Biolabs Pte Ltd A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1957640B1 (en) * 2005-11-02 2013-05-29 DSM IP Assets B.V. Modified transketolase and use thereof
CN114642735A (zh) * 2015-01-21 2022-06-21 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
KR102223521B1 (ko) * 2019-02-26 2021-03-05 한국과학기술원 안트라닐산 메틸 생성능을 가지는 재조합 미생물 및 이를 이용한 안트라닐산 메틸의 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170210698A1 (en) * 2015-09-17 2017-07-27 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
WO2021019102A2 (en) * 2019-08-01 2021-02-04 Acm Biolabs Pte Ltd A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes
CN111995677A (zh) * 2020-05-15 2020-11-27 潍坊医学院 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用
CN112129871A (zh) * 2020-09-04 2020-12-25 斯微(上海)生物科技有限公司 复合磷脂脂质体中dope和m5两种磷脂含量的检测方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SANDHYA BANGARU，等: "Structural analysis of full-length SARS-CoV-2 spikeprotein from an advanced vaccine candidate", vol. 370, pages 2 *
陈咏竹;邱峰;: "刺突蛋白与新型冠状病毒的检测和治疗" *
陈咏竹;邱峰;: "刺突蛋白与新型冠状病毒的检测和治疗", 生物医学工程学杂志, no. 02, pages 68 - 72 *

Also Published As

Publication number Publication date
WO2022171182A1 (zh) 2022-08-18

Similar Documents

Publication Publication Date Title
US20230226167A1 (en) Henipavirus vaccine
US20220249654A1 (en) Nucleic acid based combination vaccines
US20240131142A1 (en) Flavivirus vaccine
CN112292395A (zh) 用于疫苗接种的新型rsv rna分子和组合物
CN113453707A (zh) 用于疟疾疫苗的rna
US20220313813A1 (en) Rotavirus mrna vaccine
WO2020002525A1 (en) Novel lassa virus rna molecules and compositions for vaccination
KR20230164648A (ko) SARS-CoV-2 변이체에 대한 RNA 백신
JP2023550666A (ja) ヌクレオシド修飾ｍＲＮＡを使用する汎用インフルエンザワクチン
WO2022233287A1 (zh) 一种疫苗试剂和接种方法
US20240294580A1 (en) Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
JP2024511206A (ja) 免疫原性組成物
WO2022171182A1 (zh) 一种治疗或者预防冠状病毒病突变株的疫苗试剂
JP2023523423A (ja) ＳＡＲＳ－ＣｏＶ－２に対するワクチン及びその調製物
CN118434443A (zh) 干扰素在疫苗中作为佐剂的用途
WO2023019309A1 (en) Vaccine compositions
US20240252612A1 (en) Immunogenic compositions and uses thereof
WO2024131726A1 (zh) 一种广谱流感mRNA疫苗
US20240156949A1 (en) Nucleic Acid Based Vaccine
WO2024141784A2 (en) Broadly protective betacoronavirus vaccines and compositions
EP4408483A1 (en) Covid19 mrna vaccine
CN117286156A (zh) 一种狂犬病毒mRNA疫苗
WO2024044108A1 (en) Vaccines against coronaviruses
TW202424187A (zh) Rna分子
WO2024073005A2 (en) Exosome display compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination